Deals
While Novartis secured the biggest deal of the fourth quarter, a handful of riveting tales emerged from the bottom of the M&A list, including a zombie buyout and a bidding war. And no, we’re not talking about Metsera.
FEATURED STORIES
2026 is set to be a banner year for M&A in biopharma, as buyers facing major patent cliffs fight for a small pool of late-stage assets.
Metsera showed the biopharma world that M&A is back. Who could be next?
These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down after another failed acquisition or, in the case of Pfizer and Novo, two heavyweights duking it out over a hot obesity biotech.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
HBM Healthcare Investments, Vivo Capital, BlackRock, Omega Funds, Pivotal BioVentures, and Goldman Sachs join existing investors Frazier Healthcare Partners, Bain Capital Life Sciences, OrbiMed and RA Capital Management
Companies have raised over 6x more investment thanks to grant funding
Corteva Agriscience announced a $500,000 commitment to create the Corteva Agriscience Climate Positive Challenge to catalyze a movement toward climate-positive agriculture.
Pharnext SA, a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big genomics data and artificial intelligence, announced its financial results for first-half 2019.
The deal is expected to close in the first half of 2020.
Development Programs to Focus on GI and Inflammation Therapies with Reduced, or No, Side Effects
Establishment of a debt financing plan for a maximum amount of 15 million euros, with IPF Partners
Edgewater Capital Partners announced that they have entered into an agreement to acquire Haematologic Technologies Incorporated, a leading provider of biologic products and GMP compliant assay development and testing services to the biopharmaceutical industry.
Reported Additional Positive Phase 2 Data Showing Ridinilazole Improved Quality of Life and Microbiome Preservation Compared to Standard of Care
Sydney, Australia, 10 October 2019: Recce Pharmaceuticals Ltd, developing a new class of synthetic antibiotics, is pleased to announce it has raised AU$6,768,444.28 in a placement to institutional, professional and sophisticated investors that will result in 26,032,478 fully paid ordinary shares being issued at AU$0.26 per share